{
    "clinical_study": {
        "@rank": "85483", 
        "acronym": "11-MM-01", 
        "arm_group": {
            "arm_group_label": "Carfilzomib, Cyclophosphamide, Dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "All eligible subjects will receive the study intervention of Carfilzomib, Cyclophosphamide, and Dexamethasone."
        }, 
        "brief_summary": {
            "textblock": "This is a dose finding pilot study to evaluate the safety and determine the maximum\n      tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone\n      (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly\n      diagnosed transplant eligible multiple myeloma. The study will also explore the efficacy of\n      Car-Cy-Dex including overall response after induction therapy, overall response at 3 and 6\n      months post ASCT, and time to progression, progression free survival, and time to next\n      therapy if it occurs within 6 months post ASCT."
        }, 
        "brief_title": "A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cytopathologically or histologically confirmed diagnosis of MM\n\n          -  Measurable disease, as indicated by one or more of the following:\n\n          -  Serum M-protein \u2265 1.0 g/dL\n\n          -  Urine Bence Jones protein \u2265 200 mg/24 hr\n\n          -  Elevated Free Light Chain as per the International Myeloma Working Group (IMWG)\n             criteria\n\n          -  Males and females \u2265 18 years of age\n\n          -  Life expectancy of more than 5 months\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n\n          -  Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN),\n             and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.5 times\n             ULN\n\n          -  Serum Creatinine Clearance(CrCl) \u2265 30 mL/min, either measured or calculated using a\n             standard formula (e.g. Cockcroft and Gault)\n\n          -  Additional Laboratory Requirements\n\n          -  Absolute neutrophil count (ANC) \u22651.0 x 109/L\n\n          -  Hemoglobin \u22658 g/dL [transfusion permitted]\n\n          -  Platelet count \u226550.0 x 109/L\n\n          -  Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony\n             stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated\n             G-CSF for at least 2 weeks\n\n          -  Patients may receive RBC or platelet transfusions, if clinically indicated, in\n             accordance with institutional guidelines\n\n          -  Written informed consent in accordance with federal, local, and institutional\n             guidelines\n\n          -  Patients must agree to practice contraception\n\n          -  Male patients must agree not to donate semen or sperm.\n\n        Exclusion Criteria:\n\n          -  Patients with non-secretory or hyposecretory MM\n\n          -  Prior treatment for MM (prior radiation therapy or dexamethasone up to 160 mg for\n             spinal cord compression is allowed.  Other limited field radiation involving \u2264 1/3 of\n             the pelvic area is also allowed)\n\n          -  Plasma cell leukemia\n\n          -  Pregnant or lactating females\n\n          -  Major surgery within 21 days prior to first dose\n\n          -  Congestive heart failure (CHF) (New York Heart Association class III to IV),\n             symptomatic ischemia, conduction abnormalities uncontrolled by conventional\n             intervention or myocardial infarction in the previous six months\n\n          -  Acute active infection requiring systemic antibiotics, antivirals, or antifungals\n             within 14 days prior to first dose\n\n          -  Patients receiving active treatment or intervention for any other malignancy or\n             patients who, at the Investigator's discretion, may require active treatment or\n             intervention for any other malignancy within 8 months of starting study treatment.\n\n          -  Serious psychiatric or medical conditions that could interfere with treatment\n\n          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the\n             first dose and/or within 14 days before study treatment\n\n          -  Contraindication to any of the required concomitant drugs, including antiviral (e.g.\n             Valacyclovir) and proton-pump inhibitor (e.g. lansoprazole).   Corticosteroid therapy\n             in a dose equivalent to dexamethasone \u2265 1.5 mg/day or prednisone \u2265 10 mg/day.\n             (Steroid use is allowed if necessary to treat spinal cord compression and/or\n             hypocalcaemia.)\n\n          -  Patients in whom the required program of oral and IV fluid hydration is\n             contraindicated, e.g. due to pre-existing pulmonary, cardiac, or renal impairment\n\n          -  Patients with primary systemic amyloidosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660750", 
            "org_study_id": "AMyC 11-MM-01", 
            "secondary_id": "CAR-IST-520"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carfilzomib, Cyclophosphamide, Dexamethasone", 
                "description": "IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "PR-171", 
                    "Kyprolis"
                ]
            }, 
            {
                "arm_group_label": "Carfilzomib, Cyclophosphamide, Dexamethasone", 
                "description": "PO on days 1, 8, and 15 every 28 days", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan"
            }, 
            {
                "arm_group_label": "Carfilzomib, Cyclophosphamide, Dexamethasone", 
                "description": "40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Decadron"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "newly diagnosed multiple myeloma", 
            "transplant eligible multiple myeloma"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dominique.durant@cshs.org", 
                    "last_name": "Dominique Durant", 
                    "phone": "310-248-8542"
                }, 
                "contact_backup": {
                    "email": "premere.knowles@cshs.org", 
                    "last_name": "Premere Sessions"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Robert Vescio, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "claudia.fortiche@tenethealth.com", 
                    "last_name": "Claudia Fortiche", 
                    "phone": "760-416-4736"
                }, 
                "facility": {
                    "address": {
                        "city": "Palm Springs", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92262"
                    }, 
                    "name": "Comprehensive Cancer Center at Desert Regional Medical Center"
                }, 
                "investigator": {
                    "last_name": "Elber Camacho, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donna.dibuono2@umassmemorial.org", 
                    "last_name": "Donna doBuono", 
                    "phone": "508-856-1959"
                }, 
                "contact_backup": {
                    "email": "Kathryn.Clarke@umassmemorial.org", 
                    "last_name": "Kathryn Clarke"
                }, 
                "facility": {
                    "address": {
                        "city": "Worcester", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01655"
                    }, 
                    "name": "University of Massachusettes Memorial"
                }, 
                "investigator": {
                    "last_name": "Rajneesh Nath, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kimberly.bartlett@dm.duke.edu", 
                    "last_name": "Kimberly Oates", 
                    "phone": "919-668-6524"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Cristina Gasparetto, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cmorin@fhcrc.org", 
                    "last_name": "Cari Morin", 
                    "phone": "206-667-6238"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center"
                }, 
                "investigator": {
                    "last_name": "William Bensinger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma", 
        "overall_official": [
            {
                "affiliation": "Academic Myeloma Consortium", 
                "last_name": "Jatin Shah, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Academic Myeloma Consortium", 
                "last_name": "Brian GM Durie, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Review of adverse events for safety and to determine the maximum tolerated dose of the combination treatment.", 
            "measure": "Adverse Events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout treatment, estimated to be 4-6 months per patients"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660750"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall response (PR, VGPR, CR, sCR)", 
                "measure": "Overall Response after induction therapy", 
                "safety_issue": "No", 
                "time_frame": "Every 28 days during induction therapy, estimated to be 4-6 months"
            }, 
            {
                "description": "Overall Response (PR, VGPR, CR, sCR) at 3 and 6 months post ASCT.", 
                "measure": "Overall Response post ASCT", 
                "safety_issue": "No", 
                "time_frame": "3 and 6 months post ASCT"
            }, 
            {
                "description": "Time to progression will be noted if it occurs within 6 months post ASCT.", 
                "measure": "Time to Progression", 
                "safety_issue": "No", 
                "time_frame": "Througout treatment and 3 and 6 months post ASCT"
            }, 
            {
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months post ASCT"
            }, 
            {
                "description": "Time to Next Therapy if occurs within 6 months post ASCT", 
                "measure": "Time to Next Therapy", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months post ASCT"
            }
        ], 
        "source": "Academic Myeloma Consortium", 
        "sponsors": {
            "collaborator": {
                "agency": "Onyx Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Academic Myeloma Consortium", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}